Here's why Eli Lilly is a no-brainer stock to buy on the dip. Concerns about Lilly's Q3 update ... company incurred in Q3 ...

Eli Lilly’s (NYSE: LLY) market isn’t out of the weeds yet but will rebound strongly in 2025. The Q3 results failed to spark a ...

The company reported revenue of $11.4 billion and adjusted earnings of $1.18 per share, well below the consensus estimates of $12.1 billion and $1.45, respectively.

Type 2 diabetes drug Mounjaro and weight-loss drug Zepbound remained the brightest stars in Lilly's lineup. Mounjaro's sales ...

Accounting for an acquisition Eli Lilly completed in August made a big impact on earnings expectations for 2024.

Third quarter Mounjaro and Zepbound sales, while up substantially versus the same period last year, grew little compared to ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...

In a report released today, Alec Stranahan from Bank of America Securities reiterated a Buy rating on Eli Lilly & Co (LLY – Research ...

Wells Fargo analyst Mohit Bansal maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) yesterday and set a price target ...

Eli Lilly (NYSE: LLY ... expenses related to the recent acquisition of Morphic Holding. The expectations Lilly missed weren't nearly as significant as the still unrealized expectation it lowered.

Shares of Eli Lilly (NYSE ... decreases in the wholesaler channel." Lilly's full-year guidance cut was mainly related to the acquisition of Morphic Holdings. The company said that the deal ...